| Literature DB >> 33486083 |
Miguel H Malespin1, Alfred Sidney Barritt2, Stephanie E Watkins3, Cheryl Schoen3, Monica A Tincopa4, Karen D Corbin5, Andrea R Mospan3, Breda Munoz3, Huy N Trinh6, L Michael Weiss7, K Rajender Reddy8, Rohit Loomba9, Nyingi Kemmer1, Anna S Lok10.
Abstract
First-line treatment for nonalcoholic fatty liver disease (NAFLD) focuses on weight loss through lifestyle modifications.1,2 Weight loss ≥5% results in reduction of steatosis and weight loss ≥10% has been associated with improvement in hepatic inflammation and fibrosis.3 The incidence and sustainability of weight loss among patients with NAFLD were estimated and associating factors identified.Entities:
Mesh：
Year: 2021 PMID： 33486083 DOI： 10.1016/j.cgh.2021.01.023
Source DB: PubMed Journal: Clin Gastroenterol Hepatol ISSN： 1542-3565 Impact factor: 13.576